Menu Search
Equities

Rhythm Biosciences Ltd

0RY:FRA

Rhythm Biosciences Ltd

Actions
  • Price (EUR)0.041
  • Today's Change0.001 / 1.23%
  • Shares traded0.00
  • 1 Year change-86.66%
  • Beta--
Data delayed at least 15 minutes, as of Jun 10 2024 14:29 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. It is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.

  • Revenue in AUD (TTM)157.67k
  • Net income in AUD-8.63m
  • Incorporated2017
  • Employees--
  • Location
    Rhythm Biosciences LtdBio21 Institute30 Flemington Road, ParkvilleMELBOURNE 3010AustraliaAUS
  • Phone+61 39614-0600
  • Fax+61 39614-0550
  • Websitehttps://www.rhythmbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.